Extended Data Fig. 2: Activation of DCs by RP@SMs. | Nature Nanotechnology

Extended Data Fig. 2: Activation of DCs by RP@SMs.

From: Biomimetic vesicles engineered from modified tumour cells act as personalized vaccines for post-surgical cancer immunotherapy

Extended Data Fig. 2: Activation of DCs by RP@SMs.

a, Schematic illustrating the uptake and activation of BMDCs by RP@SMs. b, Time-course flow-cytometry analysis of BMDC uptake of RP@SMs (PKH26-labelled RPs and PKH67-labelled SMs) (n = 3 independent biological replicates). c, Representative flow-cytometry plots and quantification of CD11c + CD80+ and CD11c + CD86+ BMDCs after 24-hour incubation with different nanoparticles (n = 3 independent biological replicates). d, IL-12 p40 and IL-6 levels in culture supernatants of BMDCs after the indicated treatments (n = 3 independent biological replicates). Data are presented as mean ± s.d. Statistical significance was assessed using two-sided one-way ANOVA followed by Tukey’s multiple-comparisons test with a confidence interval of 95%. Panel a created with BioRender.com.

Source data

Back to article page